Big Pharma Split Stock Today
| PRM Stock | CAD 13.12 0.01 0.08% |
Performance0 of 100
| Odds Of DistressOver 81
|
Big Pharma is selling at 13.12 as of the 29th of November 2024; that is 0.08% down since the beginning of the trading day. The stock's open price was 13.13. Big Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Big Pharma Split are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Financial Services | Classification Financials |
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada. BIG PHARMA operates under Asset Management classification in Canada and is traded on Toronto Stock Exchange.. The company has 1.13 M outstanding shares of which 100 shares are at this time shorted by private and institutional investors with about 1.19 days to cover all short positions. More on Big Pharma Split
Moving together with Big Stock
Moving against Big Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Big Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Big Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Big Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Asset Management & Custody Banks, Financial Services, Financials, Capital Markets, Asset Management, Financial Services (View all Sectors) | ||||
Big Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Big Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsBig Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Big Pharma's financial leverage. It provides some insight into what part of Big Pharma's total assets is financed by creditors.
| |||||
Big Pharma Split (PRM) is traded on Toronto Exchange in Canada . Big Pharma is listed under Asset Management & Custody Banks category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.83 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Big Pharma's market, we take the total number of its shares issued and multiply it by Big Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Big Pharma Split operates under Capital Markets sector and is part of Financials industry. The entity has 1.13 M outstanding shares of which 100 shares are at this time shorted by private and institutional investors with about 1.19 days to cover all short positions.
Big Pharma generates positive cash flow from operations, but has no cash available
Check Big Pharma Probability Of Bankruptcy
Big Pharma Split Risk Profiles
Although Big Pharma's alpha and beta are two of the key measurements used to evaluate Big Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.6479 | |||
| Standard Deviation | 0.9919 | |||
| Variance | 0.9839 | |||
| Risk Adjusted Performance | (0.11) |
Big Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Big Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.